New drug combo shows promise against deadly thyroid cancer

NCT ID NCT05696548

Ongoing Disease control Sponsor: National Cancer Center Hospital East Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study is testing a combination of two drugs, nivolumab and lenvatinib, in 51 people with anaplastic thyroid cancer that cannot be removed by surgery. The goal is to see if the treatment is safe and can shrink tumors. Anaplastic thyroid cancer is rare and fast-growing, so finding effective treatments is urgent.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and lenvatinib
What this could lead to: If successful, this combination could offer a new treatment option for a rare and aggressive thyroid cancer that is currently hard to treat.
What could go wrong: This is a small, early-phase trial with only 51 participants. The treatment may cause significant side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid gland undifferentiated (anaplastic) carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC THYROID CANCER

Contacts and locations

Locations

Aichi Cancer Center

Nagoya, Aichi-ken, 464-8681, Japan
Hokkaido University Hospital

Hokkaido, Hokkaido, 060-8648, Japan
Hyogo Cancer Center

Akashi, Hyōgo, 673-8558, Japan
Kobe University Hospital

Kobe, Hyōgo, 650-0017, Japan
National Cancer Center Hospital

Tokyo, Tokyo, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa, Chiba, 277-8577, Japan
Nippon Medical School Hospital

Tokyo, Tokyo, 113-8603, Japan
Osaka Metropolitan University Hospital

Osaka, Osaka, 545-8586, Japan
Tohoku University Hospital

Sendai, Miyagi, 980-8574, Japan
Yokohama City University Hospital

Yokohama, Kanagawa, 236-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.